Ta-Chiang Liu, MD, PhD, AGAF

Ta-Chiang Liu, MD, PhD, AGAF

Associate Professor, Pathology & Immunology
Associate Chief, Division of Anatomic and Molecular Pathology

Co-Director, Advanced Imaging & Tissue Analysis Core
Director, Pilot and Feasibility Program
Digestive Disease Research Cores Center

Division

  • Anatomic & Molecular Pathology

Research Lab

Education

  • MD: National Yang Ming MC (1997)
  • Post-graduate degree: Imperial College London (2003)
  • Anatomic Pathology Residency: Washington University, St. Louis, MO (2011)

Clinical Interests

  • GI & Pancreatic Pathology

Research Interests

My main research interest is in the role of Paneth cells in Crohn’s Disease. In particular, we are interested in the molecular mechanisms of how morphologic patterns of cytoplasmic antimicrobial granules are affected by genetics and environmental triggers, and their clinical relevance. Another research interest is to develop disease pathogenesis-relevant prognostic biomarkers.

Editorial Responsibilities

2013 – Present Editorial Board Member World Journal of Gastroenterology
2011 – Present Series Editor Methods in Molecular Biology Series (Oncolytic Virus)
Ad Hoc Reviewer Hepatology, Pancreas, Molecular Therapy, Gene Therapy, Cancer Gene Therapy, Cancer Treatment Reviews

Selected Publications

Publication List (PDF)

Hallden G, Hill R, Wang Y, Anand A, Liu TC, Lemoine NR, Hallenbeck P, Hawkins L, Kirn D.. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.. Molecular Therapy 2003: 8(3): 412-24., Abstract
Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, Brooks G, Lemoine NR, Kirn D.. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.. Nature Biotechnology 2003: 21(11): 1328-35., Abstract
Liu TC, Hallden G, Wang Y, Brooks G, Francis J, Lemoine NR, Kirn D.. An E1B-19kD gene deletion mutant adenovirus demonstrates tumor necrosis factor-augmented cancer selectivity and enhanced oncolytic potency.. Molecular Therapy 2004: 9(6): 786-803., Abstract
Liu TC, Wang Y, Hallden G, Anand A, Francis J, Lemoine NR, Kirn D. Functional interactions of antiapoptotic genes and tumor necrosis factor in the context of a replication-comptent adenovirus. Gene Therapy 2005: 12(17): 1333-1346, Abstract
Liu TC, Kirn D. Viruses with deletions in antiapoptotic genes as potential oncolytic agents. Oncogene 2005; 24(40): 6069-6079, Abstract
Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza R, Rabkin S, Kurtz A.. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Molecular Therapy 2006: 14(6): 789-797, Abstract
Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza R, Kurtz A, Rabkin S. Dominant-negative FGF receptor expression enhances antitumoral potency of oncolytic HSV in neural tumors. Clinical Cancer Research 2006: 12(22): 6791-6799, Abstract
Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nature Clinical Practice Oncology (Nature Review Clinical Oncology) 2007: 4(2): 101-117, Abstract
Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Research 2007: 67(2): 429-432, Abstract
Prabhakar S, Messerli S, Stemmer-Rachmimov A, Liu TC, Rabkin S, Martuza R, Breakefield XO.Treatment of schwannomas with oncolytic herpes simplex virus in mouse models of NF2. Cancer Gene Therapy 2007: 14(5): 460-467, Abstract
Liu TC, Wakimoto H, Martuza R, Rabkin S. HSV Us3(-) mutant as oncolytic strategy and synergizes with PI3K-Akt-targeting molecular therapeutics. Clinical Cancer Research 2007: 13(19): 5897-902,Abstract
Liu TC, Kirn D. Targeting the untargetable: oncolytic virotherapy for the cancer stem cell. Molecular Therapy 2007; 15(12): 2060-1, Abstract
Liu TC, Castelo-Branco P, Rabkin S, Martuza R. Trichostatin A enhances antitumoral and antiangiogenic effects of oncolytic HSV. Molecular Therapy 2008: 16 (6): 1041-7, Abstract
Park BH, Hwang TH, Liu TC, Sze D, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Daneshmand M, Pinedo HM, Bell JC, Kirn D. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. The Lancet Oncology 2008: 9 (6): 533 – 42, Abstract
Liu TC*, Hwang TH*, Park BH, Kirn D. Oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Molecular Therapy 2008: 16(9): 1637 – 42 *: equal contribution, Abstract
Liu TC, Hwang TH, Bell JC, Kirn D. Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Molecular Therapy 2008: 16 (6): 1006 – 8, Abstract
Liu TC, Kirn D. Gene therapy progress and prospects: oncolytic viruses. Gene Therapy 2008; 15 (12): 877 – 884, Abstract
Liu TC, Hwang TH, Bell JC, Kirn D. Development of targeted oncolytic therapeutics through translational research. Expert Opinion on Biological Therapy 2008: 8(9): 1381 – 91, Abstract
Liu TC, Chen IS, Lin TK, Kirn D, Tsao CJ. Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma. Lung Cancer 2009: 63(1): 151-153, Abstract
Aghi M*, Liu TC*, Rabkin S, Martuza R. Hypoxia enhances oncolytic Herpes simplex virus replication. Molecular Therapy 2009: 17(1): 51 – 56 *: equal contribution, Abstract
Chang JF, Chen PJ, Sze DY, Reid T, Bartlett D, Kirn D, Liu TC. Oncolytic virotherapy for advanced liver tumors. Journal of Cellular and Molecular Medicine 2009: 13(7): 1238-47, Abstract
Wakimoto H, Kesari S, Farrell C, Curry W Jr., Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna D, Debasitis J, Pruszak J, Martuza R, Rabkin S. Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Research 2009: 69(8): 3472-81, Abstract
Huang PI, Chang JF, Kirn D, Liu TCTargeted genetic and viral therapy for advanced head and neck cancers. Drug Discovery Today 2009:14(11-12): 570-8, Abstract
Cadwell K, Patel K, Maloney N, Liu TC, Storer CE, Xavier R, Head R, Stappenbeck TS, Virgin HW IV.. Virus-host interaction determines contributions of Crohn’s Disease susceptibility gene Atg16L1 to intestinal pathology. Cell 2010: 141(7): 1135-45, Abstract
Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA. Efficacy and Safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Molecular Therapy 2010: 18(11): 1927-36, Abstract
Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn D. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Molecular Therapy 2011: 19(10): 1913-22, Abstract
Hamilton NA, Liu TC, Cavatiao A, Mawad K, Chen L, Strasberg SS, Linehan DC, Cao D, Hawkins WG. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery 2012: 152(1): 107-13, Abstract
Hucthagowder V, Liu TC, Paciorkowski AR, Thio LL, Keller MS, Anderson CD, Herman T, Dehner LP, Grange DK, Kulkarni S. Chromosome 2p15p16.1 microdeletion syndrome: 2.5 Mb deletion in a patient with renal anomalies, intractable seizures and a choledochal cyst. European Journal of Medical Genetics 2012: 55(8-9): 485-9, Abstract
Liu TC, Nguyen T, Torbenson MS. Concurrent increase in mitosis and apoptosis in post-transplant liver biopsy: strong indication for hepatic artery thrombosis. Modern Pathology. 2012: 25(12): 1594-8, Abstract
Liu TC, Lin MJ, Montgomery EA, Singhi AD. Inflammatory fibroid polyps of the gastrointestinal tract: spectrum of clinical, morphological, and immunohistochemistry features. American Journal of Surgical Pathology. 2013: 37(4): 586-92, Abstract
Liu TC, Hamilton N, Hawkins W, Cao D. Comparison of utility of WHO classification (2004, 2010), two-tier grading system, and AJCC-TNM staging in predicting prognosis in regional well-differentiated pancreatic neuroendocrine tumors. American Journal of Surgical Pathology. 2013: 37(6): 853-9, Abstract
Singhi AD, Norwood S, Liu TC, Sharma R, Wolfgang CL, Schulick RD, Hruban RH. Acinar cell cystadenoma of the pancreas: a benign neoplasm or non-neoplastic ballooning of acinar and ductal epithelium?. American Journal of Surgical Pathology. 2013: 37(9): 1329-35, Abstract
Swanson BJ, Limketkai BN, Liu TC, Montgomery EA, Nazari K, Park J, Santangelo WC, Torbenson MS, Voltaggio L, Yearsley M, Arnold CA. Renvela crystals in the gastrointestinal tract: a new entity associated with mucosal injury. American Journal of Surgical Pathology. 2013 Sep 20 [Epub ahead of print], Abstract
Liu TC, Vachharajani N, Chapman WC, Brunt EM. Hepatocellular carcinoma in noncirrhotic livers: morphologic and immunophenotypic associations with hepatic adenoma. Modern Pathology. 2013 Sep 20 [Epub ahead of print], Abstract
VanDussen KL*, Liu TC*, Li D, Towfic F, Modiano N, Winter R, Haritunians T, Taylor KD, Dhall D, Targan SR, Xavier RJ, McGovern DP, and Stappenbeck TS.. Genetic variants synthesize to produce Paneth Cell Phenotypes that define subtypes of Crohn. Gastroenterology. 2014:146:200-209. *: equal contribution., Abstract
Liu TC, Gao F, McGovern DP, Stappenbeck TS. Spatial and temporal stability of Paneth cell phenotypes in Crohn’s Disease: Implications for prognostic cellular biomarker development.. Inflammatory Bowel Disease. 2014: 20(4): 646-51, Abstract
Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event – a study of 236 cases. American Journal of Surgical Pathology 2014: 38(7):966-72, Abstract
Lassen KG, Kuballa P, Conway KL, Patel KK, Becker CE, Peloquin JM, Villablanca EJ, Norman JM, Liu TC, Heath RJ, Becker ML, Fagbami L, Horn H, Mercer J, Yilmaz OH, Jaffe JD, Shamji AF, Bhan AK, Carr SA, Daly MJ, Virgin HW, Schreiber SL, Stappenbeck TS,. Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense.. Proceedings of the National Academy of Sciences. 2014:111(21):7741-6, Abstract
Patel KR, Liu TC, Vaccharajani N, Chapman WC, Brunt EM. . Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases.. Arch Pathol Lab Med. 2014;138(9):1193-202., Abstract
Kuhn K, Manieri N, Liu TC, Stappenbeck TS. . IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One 2014; 9(12):e114195, Abstract
Kau AL, Planer JD, Liu J, Rao S, Yatsunenko T, Trehan I, Manary MJ, Liu TC, Stappenbeck TS, Maleta KM, Ashorn P, Dewey KG, Houpt ER, Hsieh CS, Gordon JI. Functional characterization of mucosal IgA-targeted members of the gut microbiota of undernourished Malawian children. Science Translational Medicine. 2015; 7(276): 276ra24, Abstract
Ma C, Maluf H, Liu TCAcute graft versus host disease is more prevalent and severe in the lower than the upper gastrointestinal tract. Human Pathol. 2015; 46(10):1480-7, Abstract
Ma C, Park JY, Montgomery EA, Arnold CA, McDonald OG, Liu TC, Salaria SN, Limketkai BN, McGrath KM, Musahl T, Singhi AD. A Comparative Clinicopathologic Study of Collagenous Gastritis in Children and Adults: The Same Disorder With Associated Immune-mediated Diseases. Am J Surg Pathol. 2015 Jun;39(6):802-12, Abstract
Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annual Review of Pathology: Mechanisms of Disease, Vol 11. Feb 8, 2016 [Epub ahead of print],

Assistant
Lisa Schreiber
314-273-4843
lisa.schreiber@wustl.edu
BJCIH Room 3422